Lugtenburg, P. Et Al. 2017. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study. Haematologica , vol.102, no.11 , 1913-1922.

Lugtenburg, P., Avivi, I., Berenschot, H., İLHAN, ., Marolleau, J. P., Nagler, A., ... Rueda, A.(2017). Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study. Haematologica , vol.102, no.11, 1913-1922.

Lugtenburg, Pieternella Et Al. "Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study," Haematologica , vol.102, no.11, 1913-1922, 2017

Lugtenburg, Pieternella Et Al. "Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study." Haematologica , vol.102, no.11, pp.1913-1922, 2017

Lugtenburg, P. Et Al. (2017) . "Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study." Haematologica , vol.102, no.11, pp.1913-1922.

@article{article, author={Pieternella Lugtenburg Et Al. }, title={Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: The randomized MabEase study}, journal={Haematologica}, year=2017, pages={1913-1922} }